Referencias científicas

 

 Publicado en diversas fuentes

 

 
 

http://www.archives-pmr.org/article/PIIS0003999310002352/abstract?rss=yes

Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich Ataxia
Presented in part to the American College of Sports Medicine, Seattle, WA, May 28, 2009.

Bart E. Drinkard, MSPTa, Randall E. Keyser, PhDae, Scott M. Paul, MDa, Ross Arena, PhD, PTf, Jonathan F. Plehn, MDb, Jack A. Yanovski, MD, PhDc, Nicholas A. Di Prospero, MD, PhDd+

Abstract
Drinkard BE, Keyser RE, Paul SM, Arena R, Plehn JF, Yanovski JA, Di Prospero NA. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.

Objective
To determine the exercise capacity of children and adolescents with Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of idebenone treatment on exercise capacity.

Design
Exploratory endpoint in a randomized double-blind, placebo-controlled, phase II clinical trial designed to investigate the effects of idebenone on a biomarker of oxidative stress.

Setting
Exercise physiology laboratory in a single clinical research center.

Participants
Ambulatory subjects (N=48; age range, 9–17y) with genetically confirmed FA.

Intervention
Idebenone administered orally 3 times a day for a total daily dose of approximately 5, 15, and 45mg/kg or matching placebo for 6 months.

Main Outcome Measures
Peak oxygen consumption per unit time (peak VO2) and peak work rate (WR) were measured during incremental exercise testing at baseline and after treatment. Echocardiography and neurologic assessments were also completed before and after treatment.

Results
Baseline mean peak VO2 ± SD was 746±246mL/min (16.2±5.8mL/kg/min), and WR was 40±23W for all subjects. Peak VO2 and WR were correlated with short guanine-adenine-adenine allele length and neurologic function. Relative left ventricular wall thickness was increased but left ventricular ejection fraction was normal in most subjects; there was no relationship between any exercise and echocardiographic measures. There were no significant changes in mean peak VO2 or WR after idebenone treatment at any dose level relative to placebo.

Conclusions
Exercise capacity in children and adolescents with FA was significantly impaired. The basis for the impairment appears to be multifactorial and correlated to the degree of neurologic impairment. Although idebenone has previously been shown potentially to improve features of FA, idebenone treatment did not increase exercise capacity relative to placebo.

a Rehabilitation Medicine Department, Hatfield Clinical Research Center, National Institutes of Health, Bethesda, MD

b Translational Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

c Unit on Growth and Obesity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD

d Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD

e Center for the Study of Chronic Illness and Disability, George Mason University, Fairfax, VA

f Departments of Internal Medicine, Physiology and Physical Therapy, Virginia Commonwealth University, Richmond, VA

Reprint requests to Bart E. Drinkard, MSPT, National Institutes of Health, Building 10 Room 1-1469, 10 Center Dr, Bethesda, MD 20892-1604

Supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke/National Heart, Lung, and Blood Institute intramural research funds.

No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.

This trial was registered with ClinicalTrials.gov (NCT00229632).

The opinions and information contained in this article are those of the authors and do not necessarily reflect those of the National Institutes of Health, the Department of Health and Human Services, or the United States Public Health Service.

PII: S0003-9993(10)00235-2

doi:10.1016/j.apmr.2010.04.007

© 2010 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.


http://www.jneuroengrehab.com/content/7/1/30

Innovative gait robot for the repetitive practice of floor walking and stair climbing up and down in stroke patients
Stefan Hesse , Andreas Waldner and Christopher Tomelleri

Journal of NeuroEngineering and Rehabilitation 2010, 7:30doi:10.1186/1743-0003-7-30


Published: 28 June 2010

Abstract (provisional)

Background
Stair climbing up and down is an essential part of everyday's mobility. To enable wheelchair-dependent patients the repetitive practice of this task, a novel gait robot, G-EO-Systems (EO, Lat: I walk), based on the end-effector principle, has been designed. The trajectories of the foot plates are freely programmable enabling not only the practice of simulated floor walking but also stair climbing up and down. The article intended to compare lower limb muscle activation patterns of hemiparetic subjects during real floor walking and stairs climbing up, and during the corresponding simulated conditions on the machine, and secondly to demonstrate gait improvement on single case after training on the machine.

Methods
The muscle activation pattern of seven lower limb muscles of six hemiparetic patients during free and simulated walking on the floor and stair climbing was measured via dynamic electromyography. A non-ambulatory, sub-acute stroke patient additionally trained on the G-EO-Systems every workday for five weeks.

Results
The muscle activation patterns were comparable during the real and simulated conditions, both on the floor and during stair climbing up. Minor differences, concerning the real and simulated floor walking conditions, were a delayed (prolonged) onset (duration) of the thigh muscle activation on the machine across all subjects. Concerning stair climbing conditions, the shank muscle activation was more phasic and timely correct in selected patients on the device. The severely affected subject regained walking and stair climbing ability.

Conclusions
The G-EO-Systems is an interesting new option in gait rehabilitation after stroke. The lower limb muscle activation patterns were comparable, a training thus feasible, and the positive case report warrants further clinical studies.


tp://www3.interscience.wiley.com/journal/123513804/abstract?CRETRY=1&SRETRY=0

Longitudinal tracking of gait and balance impairments in cerebellar disease
Susanne M. Morton, PhD, PT 1, Ya-Weng Tseng, PhD, PT 2, Kathleen M. Zackowski, PhD, OTR 3 4 5, Jaclyn R. Daline, PT, DPT 6, Amy J. Bastian, PhD, PT 3 4 5 *
1Graduate Program in Physical Therapy and Rehabilitation Science, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
2Department of Physical Therapy, Temple University, Philadelphia, Pennsylvania, USA
3Kennedy Krieger Institute, Baltimore, Maryland, USA
4Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
5Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
6Program in Physical Therapy, Washington University School of Medicine, St. Louis, Missouri, USA

email: Amy J. Bastian (bastian@kennedykrieger.org)

*Correspondence to Amy J. Bastian, Kennedy Krieger Institute, 707 N. Broadway, Room G-04, Baltimore, MD 21205

Potential conflict of interest: Nothing to report.
Funded by:
NIH
(NICHD/NCMRR); Grant Number: grants K01 HD050369, K01 HD049476, K12 HD055931, R01 HD040289
Foundation for Physical Therapy


http://www.plosgenetics.org/article/fetchObjectAttachment.action;jsessionid=6A548BAFE7F2A0DEABA1E6AAFD928738.ambra01?uri=info%3Adoi%2F10.1371%2Fjournal.pgen.1000984&representation=PDF


http://www.orthosupersite.com/view.aspx?rid=65219

Posted on the ORTHOSuperSite June 4, 2010
Hybrid construct provides adequate correction of deformity in patients with neurological scoliosis
 

Italian orthopaedists reported a low rate of complications when treating patients with high-grade neurological scoliosis using a hybrid construct that combined lumbar pedicle screws, Universal Clamps (Zimmer) and thoracic hooks.

“The hybrid construct … appears safe and effective in the treatment of patients affected by high-grade scoliosis, providing a good correction of deformity and reducing operative time, radiation exposure and blood loss with respect to all-screws constructs,” Guido La Rosa, MD, Chief of Orthopedic Unit, Research Institute Pediatric Hospital “Bambino Gesu,” Rome, Italy, told Orthopaedics Today Europe in an interview prior to the presentation of the study at the EFORT Congress 2010.

Study design

A prospective series of 15 neurological scoliosis patients were treated by La Rosa and colleagues between 2002 and 2008 with the hybrid construct. Patients ranged in age from 10 to 17 years, and etiologies were as follows: cerebral palsy in 12 patients, Friedreich’s ataxia in two and Aicardi Syndrome in one. All patients had a preoperative Cobb angle greater than 100°, according to the study abstract.

Story continues below

ADVERTISEMENT
 
Neurological scoliosis
Neurological scoliosis with a marked hypokyphosis treated by means of bilateral all level lumbar screws plus all level Universal Clamps thoracic instrumentation. Excellent coronal correction with an optimal sagittal contouring.

Images: La Rosa G

All patients were treated by posterior access using the hybrid construct to stabilize each affected level. A secondary posterior access was used in three patients to strengthen the effect of the Universal Clamps, adding a concave costotomy. Skull traction by sling and pelvic countertraction to control obliquity were performed in all cases. Pelvic instrumentation provided iliosacral screw fixation, and two concave rods and one convex were used in all patients, the investigators wrote in their abstract.

Passing the tape under the lamina
Passing the tape under the lamina and under the concave corrective rod.
Assembling each titanium Clamp
Assembling each titanium clamp to the rod.
Tensioning of the tape
Tensioning of the tape by means of tightening-gun and tightening of the blocker at the end of correction.

Deformity correction

Final assembly
Final assembly of the hybrid construct.

The average percentage of correction was 70% (32°±7°), with an average loss of correction of 7° occurring during the mean 36-month follow-up period (range, 12–84 months). Mean operative time was 4 hours with a mean blood loss of 1800 mL. On average, six transpedicular screws (range, 4–11), seven Universal Clamps (range, 5–9) and five thoracic hooks (range, 4–6) were used in the hybrid constructs, according to the abstract.

“The amount of coronal correction is excellent and the control of the sagittal profile seems better than with all-screws assembly,” La Rosa said. “In conclusion, the overall incidence of complications has been quite similar to other corrective procedures — in particular, no neural complications have been recorded.”
 

  • Reference:

La Rosa G, Giglio G, Oggiano L. Treatment of neurological scoliosis of more than 1008 by using a hybrid contstruct (pedicle screws plus universal clamps). Paper #F484. To be presented at the EFORT Congress 2010. June 2-5, 2010. Madrid.

The ORTHOSuperSite is intended for physician use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will the ORTHOSuperSite be used for medical advice to patients.

 


http://www.citeulike.org/user/giovanni/article/7255387

Frataxin and mitochondrial Fe-S cluster biogenesis.

 
The Journal of biological chemistry (3 June 2010)

Abstract

Friedreich's ataxia is an inherited neurodegenerative disease caused by frataxin deficiency. Frataxin is a conserved mitochondrial protein that plays a role in Fe-S cluster assembly in mitochondria. Fe-S clusters are modular cofactors that perform essential functions throughout the cell. They are synthesized by a multi-step and multi-subunit mitochondrial machinery that includes a scaffold protein Isu for assembling a protein bound Fe-S cluster intermediate. Frataxin interacts with Isu, iron, and with the cysteine desulfurase Nfs1 that supplies sulfide, thus placing it at the center of mitochondrial Fe-S cluster biosynthesis.


http://www.news-medical.net/news/20100602/Motion-Therapeutics-to-launch-BalanceWear-Stabilizing-Garments-for-MS.aspx

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS
2. June 2010 05:53


For those who suffer from balance disorders and loss of mobility, promising results from a new stabilizing device may help to reestablish mobility, confidence and independence. This week, Motion Therapeutics premieres its BalanceWear™ Stabilizing Garments at the 24th Annual Meeting for the Consortium of Multiple Sclerosis Centers in San Antonio. The device is worn as a vest incorporating Balance-Based Torso-Weighting™ (BBTW™), patented technology providing stability for patients affected by many forms of balance problems.

“BalanceWear stabilizing devices address directional loss of balance, improving equilibrium, balance and mobility immediately upon application”

Current treatment for balance impairment and balance disorders include aggressive exercise. While recovery time varies depending on the patient, some require long-term assistance and years of treatment. By comparison, patients are noticing "same day" results with the new BalanceWear devices.

"BalanceWear stabilizing devices address directional loss of balance, improving equilibrium, balance and mobility immediately upon application," says Cindy Gibson-Horn PT who invented the BalanceWear stabilizing garments. "Using objective tests and measures as well as patterns of weighting the torso according to balance loss, trained professionals can custom fit the garment and weights exclusive to each patient need."

Gibson-Horn, et al evidence-based research findings have been published in several medical periodicals including the Journal of Neurologic Physical Therapy, Archives of Physical Medicine, and Journal of Neuro-rehabilitation and Neural Repair featuring functional improvement of patients with ataxia, multiple sclerosis, and parietal stroke.

Balance-Based Torso-Weighting method was developed to correct and support balance disorders associated with Multiple Sclerosis (MS), brain injuries, Parkinson's disease, and stroke as well as other destabilizing health issues. The BalanceWear stabilizing devices assist in postural orientation and equilibrium, abnormal automatic postural control responses, and directional postural control dysfunction.

SOURCE Motion Therapeutics Inc.
 


http://www.ncbi.nlm.nih.gov/pubmed/20111601

Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.
Gonzalez-Cabo P, Ros S, Palau F.

Laboratory of Genetics and Molecular Medicine, Instituto de Biomedicina de Valencia, CSIC, Valencia, Spain.

Abstract
BACKGROUND: Friedreich ataxia is a neurodegenerative disease caused by the lack of frataxin, a mitochondrial protein. We previously demonstrated that frataxin interacts with complex II subunits of the electronic transport chain (ETC) and putative electronic transfer flavoproteins, suggesting that frataxin could participate in the oxidative phosphorylation. METHODS AND FINDINGS: Here we have investigated the effect of riboflavin and its cofactors flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) in Saccharomyces cerevisiae and Caenorhabditis elegans models of frataxin deficiency. We used a S. cerevisiae strain deleted for the yfh1 gene obtained by homologous recombination and we assessed growth in fermentable and non-fermentable cultures supplemented with either riboflavin or its derivates. Experiments with C. elegans were performed in transient knock-down worms (frh-1[RNAi]) generated by microinjection of dsRNA frh-1 into the gonads of young worms. We observed that FAD rescues the phenotype of both defective organisms. We show that cell growth and enzymatic activities of the ETC complexes and ATP production of yfh1Delta cells were improved by FAD supplementation. Moreover, FAD also improved lifespan and other physiological parameters in the C. elegans knock-down model for frataxin. CONCLUSIONS/SIGNIFICANCE: We propose that rescue of frataxin deficiency by FAD supplementation could be explained by an improvement in mitochondrial respiration. We suggest that riboflavin may be useful in the treatment of Friedreich ataxia.


http://clinicaltrials.gov/ct2/show/NCT00824512

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
This study is currently recruiting participants.
Verified by Ipsen, May 2010
First Received: January 15, 2009 Last Updated: May 26, 2010 History of Changes
Sponsor: Ipsen
Information provided by: Ipsen
ClinicalTrials.gov Identifier: NCT00824512

Purpose
The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia


Condition Intervention Phase
Friedreich Ataxia
Drug: EGb 761 120 mg bid
Drug: Placebo 1 tablet BID
Phase II



Study Type: Interventional
Study Design: Allocation: Randomized
Control: Placebo Control
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia


Resource links provided by NLM:


Genetics Home Reference related topics: deoxyguanosine kinase deficiency Friedreich ataxia Marinesco-Sjögren syndrome mitochondrial neurogastrointestinal encephalopathy disease
MedlinePlus related topics: Exercise and Physical Fitness Friedreich's Ataxia
Drug Information available for: EGB 761
U.S. FDA Resources


Further study details as provided by Ipsen:


Primary Outcome Measures:
•Creatine rephosphorylation rate (sec-1) post-exercise using P-31 NMR spectroscopy, calculated with correction according to muscular pH. [ Time Frame: Assessed at the baseline (W0) and W12. ] [ Designated as safety issue: No ]


Secondary Outcome Measures:
•Post-exercise skeletal muscle perfusion (ml/min/100 g of tissue) [ Time Frame: Assessed at the baseline (W0) and W12 ] [ Designated as safety issue: No ]

•Peak post exercise perfusion (ml/mn/100 g of tissue) [ Time Frame: Assessed at the baseline (W0) and W12 ] [ Designated as safety issue: No ]

•Adverse events [ Time Frame: Assessed at the baseline (W0) and W12 ] [ Designated as safety issue: Yes ]


Estimated Enrollment: 20
Study Start Date: June 2008
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
EGb 761® 120 mg Drug: EGb 761 120 mg bid
EGb 761® 120 mg bid, orally for 12 to 14 weeks
2: Placebo Comparator
Placebo 1 tablet Drug: Placebo 1 tablet BID
Placebo 1 tablet BID, orally for 12 to 14 weeks


Eligibility


Ages Eligible for Study: 12 Years to 22 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
Inclusion Criteria:

•Friedreich ataxia diagnosis confirmed by evidenced mutation expansion of Frataxin gene
•Ambulatory patient, with depressed tendon reflexes and pyramidal syndrome associated or not to a loss of position or vibration senses or dysarthria
•Patient able to perform the tests of the study
Exclusion Criteria:

•Severe cardiac disease as assessed by echocardiography performed at least within 6 months before screening or during the wash out period (4 weeks)
•Absolute contra-indication to NMR examination: iron and any magnetic objects implanted in the whole body, e.g. some neurostimulators, cardiac pace-makers, vascular clips and other implanted orthopaedic prosthesis
•Patient who did not deplete at baseline PCr pool by more than 30 % during the exercise bout
•Any continuous use of the following forbidden medications:
•other antioxidant such as idebenone, coenzyme Q, vitamin E/C taken for less than 4 weeks prior study treatment start (ie for antioxidant drugs a mandatory wash-out period of 4 weeks prior study drug start has to be observed),
•any other vasodilators
•tranquilizer such as benzodiazepine, meprobamate or buspirone, and/or antidepressant (only one), at non stable dose
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824512

Contacts
Contact: Ipsen Recruitment Enquiries clinical.trials@ipsen.com

Locations
France
Hospital Necker Enfants Malades Recruiting
Paris, France, 75015
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Cécile Merdrignac, MD Ipsen


Responsible Party: Ipsen ( Cecile Merdrignac, Medical Development Director )
ClinicalTrials.gov Identifier: NCT00824512 History of Changes
Other Study ID Numbers: 2-39-00240-133
Study First Received: January 15, 2009
Last Updated: May 26, 2010
Health Authority: France: Afssaps - French Health Products Safety Agency
 

ClinicalTrials.gov processed this record on June 21, 2010

 


 

Volver a la Portada